This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Combining radiation therapy with immunotherapy has been shown to improve the effectiveness of immune responses against tumors. While radiation can have a direct killing effect on cancer cells, Dr. Stephen Kron is exploring an alternative possibility—that radiation’s true benefits come from its effect on tumor blood vessels. His team has already shown that lower doses of radiation (compared to those required to kill tumors) can disrupt tumor blood vessels and enable improved delivery of checkpoint immunotherapy drugs. Now, Dr. Kron is focused on optimizing this approach and evaluating whether it’s able to improve the tumor-targeting activity of T cells in mice bearing melanoma or other tumors. If successful, using this strategy in the clinic could allow cancer patients to be treated with smaller and fewer doses of both radiation and immunotherapy drugs, while leading to increased benefits and decreased side effects.
University of Chicago | All Cancers | 2017
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).